Adiponectin and resistin modulate the progression of Alzheimer's disease in a metabolic syndrome model
Cisternas, Pedro
Universidad de O'Higgins
Gherardelli, Camila
Pontificia Universidad Catolica de Chile
Gutierrez, Joel
Pontificia Universidad Catolica de Chile
Salazar, Paulina
Pontificia Universidad Catolica de Chile
Mendez-Orellana, Carolina
Pontificia Universidad Catolica de Chile
Wong, G. William
Johns Hopkins University
Inestrosa, Nibaldo C.
Journal
Frontiers in Endocrinology
ISSN
1664-2392
Open Access
gold
Volume
14
Metabolic syndrome (MetS), a cluster of metabolic conditions that include obesity, hyperlipidemia, and insulin resistance, increases the risk of several aging-related brain diseases, including Alzheimer's disease (AD). However, the underlying mechanism explaining the link between MetS and brain function is poorly understood. Among the possible mediators are several adipose-derived secreted molecules called adipokines, including adiponectin (ApN) and resistin, which have been shown to regulate brain function by modulating several metabolic processes. To investigate the impact of adipokines on MetS, we employed a diet-induced model to induce the various complications associated with MetS. For this purpose, we administered a high-fat diet (HFD) to both WT and APP/PSN1 mice at a pre-symptomatic disease stage. Our data showed that MetS causes a fast decline in cognitive performance and stimulates A beta(42) production in the brain. Interestingly, ApN treatment restored glucose metabolism and improved cognitive functions by 50% while decreasing the A beta(42/40) ratio by approximately 65%. In contrast, resistin exacerbated Ab pathology, increased oxidative stress, and strongly reduced glucose metabolism. Together, our data demonstrate that ApN and resistin alterations could further contribute to AD pathology.
Name
document.pdf
Type
Main Article
Size
27.16 MB
Format
Adobe PDF
Checksum
(MD5):e435430e5de462bf27b1476e9bedc774